BioMarker’s aging-intervention technologies provide us the pathway for the development of dietary supplements and other nutraceuticals with potent health benefits. By screening for compounds and components which mimic the impact of our extended life span models, especially calorie restriction (CR), we can design and develop products that help prevent disease and promote overall health.
There are remarkable health benefits to be extracted through mimicry of the CR and other extended life span models, including:
The delay or prevention of the onset of cancer, diabetes, cardiovascular disease, metabolic disease (diabetes), and neurodegenerative disease; (AD, PD);
Increased insulin sensitivity and glucose disposal and resistance to age-associated hyperinsulinemia;
Preservation and enhancement the immune responsiveness of older individuals;
Prolongation of the healthy period near the end of life; and finally
Extension of the maximum lifespan.
To achieve these benefits, we screen nutraceutical candidates for activity in our animal models, using DNA chips and proteomic analysis to monitor the expression response of genes and proteins. This information can be used to guide the selection of bioactives which positively impact the biomechanisms associated with the CR or other extended life span model (see our Technology Platform page for details). Such mechanisms may include:
Reducing oxidative stress and damage;
Preventing deterious age-related changes in gene expression;
Changing energy metabolism;
Reducing DNA damage and increasing DNA repair;
Effecting neuroendocrine changes which extend lifespan; and
Slowing the rate of chromosome telomere shortening.
"Raising the Bar" in Nutraceuticals
At BioMarker, however, we do not stop with in vitro testing and animal model screening and design. We are putting our work to the test, by measuring demonstrable, proven biomarkers of health – such as cholesterol maintenance and reduction, weight management, and blood glucose control – in human clinical testing environments designed to provide properly controlled evaluation (including placebo controls and double-blinding, as appropriate) and statistically relevant results.
By associating our aging-intervention technology with proven biomarkers of health, and doing so in a rigorous clinical setting, we expect to ‘raise the bar’ in nutraceutical development, offering superior products with both scientific and clinical validation.
